Relates to capping cost sharing for antiviral COVID-19 therapeutics

Introduced

In Committee

Floor

Crossed Over

Passed

Enacted

Overview Bill text 1 History 1 Sponsors

S6925 — · 898 words Open full page ↗

Sign in to read the full text

The document summary and details above are public. The full text is available to signed-in accounts.

Create a free account Sign in

PASSAGE PROBABILITY

1% Unlikely

Why this number

Stage base In Committee — base rate 5%, measured from NY's completed sessions
Momentum -5 26/100 from the pace of recorded action
Time since last action -22 564 days quiet

A transparent scoring model over stage, momentum, recency, sponsorship and recorded votes — not a trained predictor. Treat it as a way to rank attention, not as a forecast.